News | April 25, 2026
Bayer’s comeback gains speed as CEO warns: “The Work Isn’t Complete. Yet"
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
This marks the second indication for which gumokimab has gained NDA review acceptance
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
While Merck can appeal, Halozyme said it expects the order to hold
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
Subscribe To Our Newsletter & Stay Updated
